Biogen and Eisai have said that the EMA's human medicines committee looks unlikely recommended approval of their Alzheimer's drug Aduhelm when it comes up for discussion next month.
AbbVie has reported that a subcutaneous infusion of Parkinson's disease candidate ABBV-951 was more effective than standard oral therapy in a phase 3 trial, paving the way for regulatory fi
Eli Lilly has followed through on its plan to file for approval of its Alzheimer's disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against
Nicolas Vachicouras, CEO of Neurosoft Bioelectronics, tells us how Neurosoft's electrode implant aims to reduce inflammation and scar tissue for patients, provide higher quality brain recor
A hospital trust has become the first in the UK to deploy a gaming system developed by Swiss company MindMaze that is intended to help patients suffering a stroke to repair their brains.
A drug originally developed for high blood pressure could find a new use in the treatment of Huntington's disease, thanks to an artificial intelligence-based drug discovery programme at Spa